Discovery of the First BRD4 Second Bromodomain (BD2)-Selective Inhibitors
Journal of Medicinal Chemistry · 12.12.2024 · 67 (23) · 21577-21616
DOI: 10.1021/acs.jmedchem.4c02516 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 27.11.2024. Verfasst von Junhua Li und 14 weiteren Autor:innen. Beteiligte Einrichtung: China-New Zealand Joint Laboratory of Biomedicine and Health, State Key Laboratory of Respiratory Disease, Guangdong Provincial Key Laboratory of Bio…. Hauptthemen laut MEDLINE: Transcription Factors, Cell Cycle Proteins. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 93 Literaturangaben. Gefördert von: National Key Research and Development Program of China, State Key Laboratory of Respiratory Disease, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Pan-BD2 inhibitors have been shown to retain an antileukemia effect and display less dose-limiting toxicities than pan-BET inhibitors. However, it is necessary to consider the potential off-target toxicity associated with the inhibition of four BET BD2 proteins. To date, no BRD4 BD2 domain selective inhibitor has been reported. Based on our previous pan-BD2 inhibitor 12 (XY153), we successfully identified 16o (XY221) as the first BRD4 BD2-selective inhibitor. 16o demonstrated potent binding affinity for BRD4 BD2 (IC50 = 5.8 nM), along with high pan-BD2 selectivity (667-fold over BRD4 BD1) and BRD4 BD2 domain selectivity (9-32-fold over BRD2/3/T BD2). The BRD4 BD2 selectivity of 16o was further confirmed by the BLI assay, showing 66-144-fold selectivity over other BET BD2 domains. 16o exhibited good liver microsomal stability (T1/2 > 120 min) and pharmacokinetic properties (F = 13.1%). These data indicate that 16o may serve as a valuable candidate for BRD4 BD2 advancing epigenetic research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- China-New Zealand Joint Laboratory of Biomedicine and Health, State Key Laboratory of Respiratory Disease, Guangdong Provincial Key Laboratory of Biocomputing, Institute of Drug Discovery, Guangzhou Institutes of Biomed…
- Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China.
- School of Pharmaceutical Sciences, Jilin University, Changchun, Jilin 130021, China.
- Analysis and Testing Center, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, No. 190 Kaiyuan Avenue, Guangzhou 510530, China.
- Guoke Ningbo Life Science and Health Industry Research Institute, Ningbo, Zhejiang 315010, China.
ORCID-Profile: Junhua Li, Qiuping Xiang, Yan Zhang, Bin Lin, Linxiang Zhao, Yong Xu
Förderung
- National Key Research and Development Program of China
- State Key Laboratory of Respiratory Disease
- China Postdoctoral Science Foundation
- Youth Innovation Promotion Association of the Chinese Academy of Sciences
- Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences
- National Natural Science Foundation of China
- Guangdong Provincial Postdoctoral Special Funding
- Guangdong Province
Zitieren
APA
Li, J., Hu, Q., Zhu, R., Dong, R., Shen, H., Hu, J., Zhang, C., Zhang, X., Xu, T., Xiang, Q., Zhang, Y., Lin, B., Zhao, L., Wu, X., & Xu, Y. (2024). Discovery of the First BRD4 Second Bromodomain (BD2)-Selective Inhibitors. Journal of Medicinal Chemistry, 67(23), 21577-21616. https://doi.org/10.1021/acs.jmedchem.4c02516
Vancouver
Li J, Hu Q, Zhu R, Dong R, Shen H, Hu J, et al. Discovery of the First BRD4 Second Bromodomain (BD2)-Selective Inhibitors. Journal of Medicinal Chemistry. 2024;67(23):21577-21616. doi:10.1021/acs.jmedchem.4c02516
BibTeX
@article{Li2024,
author = {Li, Junhua and Hu, Qingqing and Zhu, Run and Dong, Ruibo and Shen, Hui and Hu, Jiankang and Zhang, Cheng and Zhang, Xiaohan and Xu, Tingting and Xiang, Qiuping and Zhang, Yan and Lin, Bin and Zhao, Linxiang and Wu, Xishan and Xu, Yong},
title = {Discovery of the First BRD4 Second Bromodomain (BD2)-Selective Inhibitors},
journal = {Journal of Medicinal Chemistry},
year = {2024},
volume = {67},
number = {23},
pages = {21577--21616},
doi = {10.1021/acs.jmedchem.4c02516}
}
EUVIMED